Passage of ‘Emily’s Law’ draws praise from Rx tech certification board
WASHINGTON The Ohio Legislature’s passage of the so-called “Emily’s Law” Tuesday drew praise from the Pharmacy Technician Certification Board.
The law requires a competency test and background check for pharmacy technicians in the state. The name comes form Emily Jerry, a young girl who died after receiving the wrong IV solution. The PTCB, which issued the statement Friday, said Jerry’s case demonstrates that errors in pharmacy can have dire consequences.
“In addition to efforts in Ohio, pharmacy associations across the country are invested in the protection of the public,” the organization said in the statement.
The PTCB conducted a poll last year showing that 91 percent support strong regulations across the country to protect patient safety by requiring that pharmacy technicians be trained and certified, while 13 percent were aware that there are no nationwide requirements for the training and certification of pharmacy technicians.
Women’s Health announces additions to executive team
AVON, Conn. Women’s Health USA announced Thursday promotions that would affect the make-up of its executive team.
Women’s Health has said that Patrick Murphy will serve as president and COO, reporting to Robert Patricelli, chairman and CEO.
Murphy rececently served at Women’s Health as EVP and serves concurrently as SVP and CFO of Evolution Benefits a companion company to Women’s Health.
Additionally, Brian Pskowski has been promoted to the role of EVP of finance and administration Women’s Health subsidiary In Vitro Sciences. Prior to this promotion, Pskowski served as Women’s Health’s CFO for several years, reports said.
And Michael Pascetta has been tapped for SVP and CFO of Women’s Health, taking over for Pskowski. Pascetta has served Women’s Health as CFO of an operating divisions for four years.
GlaxoSmithKline begins phase 3 trial for coronary heart disease treatment
LONDON GlaxoSmithKline has started its first phase 3 clinical trial to determine the efficacy of the investigational Lp-PLA2 inhibitor darapladib, for adults with chronic coronary heart disease, GSK announced Thursday.
The Stabilization of Atherosclerotic Plaque By Initiation of Darapladib Therapy, or STABILITY study, will include more than 15,000 patients from 39 studies.
“Despite major advances in medical treatment, coronary heart disease remains the leading cause of death worldwide, and new approaches are needed to help reduce this burden to patients and society,” GlaxoSmithKline senior vice president for drug discovery Patrick Vallance said in a statement. “GSJ is initiating the large STABILITY trial with darapladib as part of a phase 3 program to determine if this novel medication could improve people?s lives by reducing the risk of cardiovascular events.”